PureTech Health PLC (PRTC)
| Market Cap | 1.42B |
| Revenue (ttm) | 11.77M |
| Net Income (ttm) | 4.57M |
| Shares Out | 28.66M |
| EPS (ttm) | -6.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,472 |
| Open | 48.76 |
| Previous Close | 51.00 |
| Day's Range | 47.50 - 49.48 |
| 52-Week Range | 33.00 - 65.90 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About PRTC
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic ...
Financial Performance
In 2020, PRTC's revenue was $11.77 million, an increase of 20.00% compared to the previous year's $9.81 million. Earnings were $4.57 million, a decrease of -98.75%.
Financial StatementsNews
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
BOSTON--(BUSINESS WIRE)--PureTech Health announced that its Founded Entity, Vedanta Biosciences, has appointed Dr. Simona Levi as Chief Legal Officer and Corporate Secretary.
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the a...
PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile and Exercise of $23.8M Option by BARDA
PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 M...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that ...
PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili announces topline results from Shionogi Phase 2 study of SDT-001 (Japanese version of AKL-T01).
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysf...
BOSTON--(BUSINESS WIRE)--PureTech Health today announced the publication of a research paper in Nature Metabolism using its Glyph technology platform.
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
BOSTON--(BUSINESS WIRE)--PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to VOR33.
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech Health (Nasdaq: PRTC, LSE: PRTC) today announces its half-yearly results for the six months ended June 30, 2021.
PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
BOSTON--(BUSINESS WIRE)--PureTech announced the presentation of the Phase 1 multiple ascending dose & food effect study of LYT-100 at the virtual ERS Congress.
PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry ...
BOSTON--(BUSINESS WIRE)--PureTech's Akili and TALi completed an agreement for Akili to license TALi's technology designed to address early childhood attention impairments.
PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer
BOSTON--(BUSINESS WIRE)--PureTech appointed Dr. Julie Krop as Chief Medical Officer. She will oversee the advancement of PureTech's clinical-stage Wholly Owned Pipeline.
Imbrium Therapeutics To Develop PureTech's Non-Opioid Candidate For Chronic Bladder Condition
Imbrium Therapeutics has exercised a license option to develop PureTech Health plc's (NASDAQ: PRTC) LYT-503/IMB-150 (formerly designated as ALV-107), a non-opioid therapeutic candidate for interstitial ...
PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystiti...
BOSTON--(BUSINESS WIRE)--PureTech announced that Imbrium has exercised a license option under the companies' R&D collaboration agreement to develop PureTech's LYT-503/IMB-150.
PureTech: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--Notice of Half-Yearly Results
PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment f...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD
PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing
Vedanta Biosciences Completes $68 Million Series D Financing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from ...
PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar S...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem C...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Announces Collaboration with Janssen to Develop eHSC Transplants Combined with a Bi-Specific Antibody Therapy for AML
PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Te...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Collaborates with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms
PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer
PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership will evaluate BeiGene's tislelizumab, in combinati...
PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients ...
BOSTON--(BUSINESS WIRE)--PureTech Announces Clinical Trial & Supply Agreement with BeiGene to Evaluate LYT-200 & Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Infla...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...